Targeting specific DNA regions to treat resistant breast cancers
Official title: Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers
Funded at University of Texas Hlth Science Center · NIH-11075874 · Data updated 2026-11-12
This study is testing a new drug called Carbazole Blue that aims to treat tough-to-beat breast cancer by targeting specific parts of the cancer cells' DNA, hoping to help patients while causing fewer side effects than usual treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $484,169 |
| NIH project number | 5R01CA277498-03 |
| Project ID | NIH-11075874 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast cancer who have shown resistance to current therapies.
✕Less likely to help
Patients with early-stage breast cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates a novel drug, Carbazole Blue (CB), which targets specific AT-rich regions of DNA in breast cancer cells. The approach aims to exploit the unique DNA repair mechanisms of cancer cells while minimizing damage to normal cells. By focusing on these specific DNA regions, the research seeks to develop a treatment that avoids the common side effects associated with traditional DNA-targeting therapies. The study will utilize cell lines and patient-derived samples to evaluate the effectiveness of CB in combating therapy-resistant breast cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with therapy-resistant breast cancers.
How similar studies have gone: While targeting specific DNA regions is a novel approach, previous research has shown promise in developing targeted therapies for cancer treatment.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Rao, Manjeet Kumar — University of Texas Hlth Science Center
- Study coordinator: Rao, Manjeet Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.